Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 
CADUS CORPORATION
(Name of Issuer)

Common Stock, $0.01 Par Value
(Title of Class of Securities)

 127639-10-2(CUSIP Number)

Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 14, 2013
(Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  o

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 2 of 8  
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
GlaxoSmithKline plc
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                                                                            (a) o
                                                                                                                            (b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)    o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
-0-
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
-0-
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES        o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
14
TYPE OF REPORTING PERSON
CO
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 3 of 8  
 
Item 1.              Security and Issuer.
 
This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on May 20, 1998 (the “Original Schedule 13D”) with respect to the shares of common stock, par value $0.01 per share (the “Common Stock”), of Cadus Corporation, a Delaware corporation (the “Issuer”), by SmithKline Beecham Limited f/k/a SmithKline Beecham plc (“SKB”), an indirect wholly owned subsidiary of GlaxoSmithKline plc, and GlaxoSmithKline LLC f/k/a SmithKline Beecham Corporation (“GSK LLC”), an indirect wholly-owned subsidiary of GlaxoSmithKline plc.  Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.  The Issuer’s principal executive offices are located at 767 Fifth Avenue, New York, New York 10153.
 
Item 2.              Identity and Background.
 
The response set forth in Item 2 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it as set forth below:
 
This Statement is being filed on behalf of GlaxoSmithKline plc, a public limited company organized under the laws of England and Wales. GlaxoSmithKline plc and its subsidiaries constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer healthcare products with its principal offices located at 980 Great West Road, Brentford Middlesex TW8 9GS England.  Set forth in Schedule 1 to this Statement are the name, business address and present principal occupation or employment of each executive officer and director of GlaxoSmithKline plc.  The Common Stock which is the subject of this Statement was held of record by SKB and GSK LLC.
 
During the last five years prior to the date hereof, neither GlaxoSmithKline plc nor, to the best knowledge of GlaxoSmithKline plc, any of the other persons with respect to whom information is given in response to this Item 2 has been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.
 
The citizenship of each executive officer and director of GlaxoSmithKline plc is set forth in Schedule 1 to this Statement.
 
Item 4.              Purpose of Transaction.
 
The response set forth in Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following:
 
On June 14, 2013, each of SKB and GSK LLC sold 330,481 shares of Common Stock (in the aggregate, the “Sold Shares”) to a purchaser for an aggregate purchase price of $892,298.70.
 
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 4 of 8  
 
Item 5.              Interest in Securities of the Issuer.
 
The response set forth in Item 5 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
 
(a) – (b) On June 14, 2013, upon the disposition of all of the Sold Shares, GlaxoSmithKline plc ceased to beneficially own any shares of Common Stock.
 
(c)   Except as described herein, no transactions in shares of Common Stock were effected during the past 60 days by GlaxoSmithKline plc.
 
(d)   Not applicable.
 
(e)          On June 14, 2013, upon the disposition of all of the Sold Shares, GlaxoSmithKline plc ceased to be the beneficial owner of more than five percent of the shares of Common Stock.
 
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 5 of 8  
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
 
 
 
GLAXOSMITHKLINE PLC
 
 
 
   /s/ Victoria A. Whyte              
 
By: Victoria A. Whyte
Title: Company Secretary
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 6 of 8  
 
 
SCHEDULE I

Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
             
Board of Directors
            
             
Sir Andrew Witty
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and Chief Executive Officer
  
British
             
Simon Dingemans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and Chief Financial Officer
  
British
             
Dr. Moncef Slaoui
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and
Chairman Global Research & Development and Vaccines
  
Moroccan, Belgian & US
             
Sir Christopher Gent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chairman and Company Director
  
British
             
Professor Sir Roy Anderson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Dr. Stephanie Burns
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Stacey Cartwright
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Judy Lewent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
 
             
Sir Deryck Maughan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Dr. Daniel Podolsky
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 7 of 8  
 
Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
             
Tom de Swaan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
Dutch
             
Sir Robert Wilson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Lynn Elsenhans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Jing Ulrich
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Hans Wijers
 
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
 
  
Company Director
  
Dutch
 
 
Corporate Executive Team
            
             
Sir Andrew Witty
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and Chief Executive Officer
  
British
             
Simon Dingemans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and Chief Financial Officer
  
British
             
Dr. Moncef Slaoui
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director
Chairman Global Research & Development and Vaccines
  
Moroccan, Belgian & US
             
Simon Bicknell
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President, Governance, Ethics and Assurance
  
British
             
Deirdre Connelly
  
5 Crescent Drive,
Philadelphia, PA
19112
  
President, North America
Pharmaceuticals
  
US
             
 
 
 
 
 
CUSIP No.             127639-10-2
 
SCHEDULE 13D/A
Page 8 of 8  
 
Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
             
Abbas Hussain
  
150 Beach Road
22-00 Gateway West
189720
Singapore
  
President, Europe & Emerging Markets & Asia Pacific
 
  
British
             
William Louv
  
Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709
  
Senior Vice President, Core Business Services
  
US
             
David Redfern
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Strategy Officer
  
British
             
Christophe Weber
  
Avenue Fleming, 20
B-1300 Wavre
Belgium
  
President, Vaccines
  
French
             
Claire Thomas
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President,
Human Resources
  
British
             
Philip Thomson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President, Global Communications
  
British
             
Daniel Troy
  
5 Crescent Drive
Philadelphia, PA
19112
  
Senior Vice President & General Counsel
  
US
             
Dr. Patrick Vallance
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Pharmaceuticals R&D
  
British
             
Emma Walmsley
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Consumer Healthcare Worldwide
  
British
             
Roger Connor
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Global Manufacturing & Supply
  
British